Results 21 to 30 of about 17,680 (157)
, 2021 Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma.
David Hogg +12 more
core +1 more source
, 2021 International audienceIn diffuse large B-cell lymphoma (DLBCL), tumor-infiltrating T lymphocytes (TILs) are involved in therapeutic responses. However, tumor-specific TILs can be dysfunctional, with impaired effector functions.
Foucher, Etienne +25 more
core +1 more source
Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor
, 2016 The durability and efficacy of anti-human PD1 monoclonal antibodies (PD1 mAb) vary across different malignancies. Although an absence of tumor-infiltrating cytotoxic T lymphocytes has been identified as a cause for resistance to PD1 mAb, the presence of ...
Stephen J. Blake +15 more
core +1 more source
, 2017 This record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete.
Australian Red Cross Society, National Office
core
[Greenbrier & Eastern R. R. Co, Engine Drawing Card, Sketch No. 7159]
, 1921 This engine drawing card was created for Greenbrier & Eastern Railroad, Class 12-40 1/4 E. Section N-12 1/4 E. Sketch 7159. Copy Spec.
Baldwin Locomotive Works
core
, 2022 20.500.12530/87912Improved selection of cancer patients who are most likely to respond to immune checkpoint inhibitors remains an unmet clinical need.
Salvador, Fernando +27 more
core +1 more source
State v. Tipton Appellant\u27s Brief Dckt. 47118 [PDF]
, 2020 https://digitalcommons.law.uidaho.edu/not_reported/7159/thumbnail ...
core
Organ weights at PD1 in control and IF offspring.
, 2022 Organ weights at PD1 in control and IF offspring.
Alaa Alkhalefah (12225241) +4 more
core +1 more source
, 2017 Background Antibodies blocking the inhibitory checkpoint PD1, expressed by T lymphocytes, and kinase inhibitors of BRAF and MEK (MAPKi) are mainstays of current treatment for patients with metastatic melanoma.
Lidia Giraudo +13 more
core +1 more source
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. [PDF]
, 2013 Recently, the possibility of PD1 pathway-targeted therapy has been extensively studied in various human malignant tumors. However, no previous study has investigated their potential application for soft-tissue sarcomas (STS).
Jun Sang Bae +35 more
core +1 more source